Patent intelligence · US
US 11673893
CDK inhibitors and their use as pharmaceuticals
CDK inhibitors and their use as pharmaceuticals
Patent details — US 11673893
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 13, 2023
- Expiration
- Jun 8, 2043
- Applicant
- Prelude Therapeutics, Incorporated
- Claims
- 10
- CPC classes
- A61K, A61K31/4545, A61K31/506, A61P
Quick answer
US 11673893 (CDK inhibitors and their use as pharmaceuticals) is held by Prelude Therapeutics, Incorporated. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Prelude Therapeutics, Incorporated
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/4545, A61K31/506, A61P, A61P35/00
More from Prelude Therapeutics, Incorporated
Related pharmaceutical patents in our USPTO index.
-
US 12414953
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 12129262
CDK inhibitors and their use as pharmaceuticals
granted -
US 11939340
CDK inhibitors and their use as pharmaceuticals
granted -
US 11702423
BRM targeting compounds and associated methods of use
granted -
US 11685744
CDK inhibitors and their use as pharmaceuticals
granted -
US 11622970
BCL-2 inhibitors and their use as pharmaceuticals
granted -
US 11524962
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
granted
Frequently asked questions
What is US patent 11673893?
US 11673893 (CDK inhibitors and their use as pharmaceuticals) is held by Prelude Therapeutics, Incorporated. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11673893?
Prelude Therapeutics, Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.
When does US 11673893 expire?
Our index shows an expiration date of Jun 8, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.